|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM357511883 |
| 003 |
DE-627 |
| 005 |
20250304202424.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202303080
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1191.xml
|
| 035 |
|
|
|a (DE-627)NLM357511883
|
| 035 |
|
|
|a (NLM)37249019
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kuen, Da-Sol
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.09.2023
|
| 500 |
|
|
|a Date Revised 08.09.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a To demonstrate potent efficacy, a cancer vaccine needs to activate both innate and adaptive immune cells. Personalized cancer vaccine strategies often require the identification of patient-specific neoantigens; however, the clonal and mutational heterogeneity of cancer cells presents inherent challenges. Here, extracellular nanovesicles derived from alpha-galactosylceramide-conjugated autologous acute myeloid leukemia (AML) cells (ECNV-αGC) are presented as a personalized therapeutic vaccine that activates both innate and adaptive immune responses, bypassing the need to identify patient-specific neoantigens. ECNV-αGC vaccination directly engages with and activates both invariant natural killer T (iNKT) cells and leukemia-specific CD8+ T cells in mice with AML, thereby promoting long-term anti-leukemic immune memory. ECNV-αGC sufficiently serves as an antigen-presenting platform that can directly activate antigen-specific CD8+ T cells even in the absence of dendritic cells, thereby demonstrating a multifaceted cellular mechanism of immune activation. Moreover, ECNV-αGC vaccination results in a significantly lower AML burden and higher percentage of leukemia-free survivors among cytarabine-treated hosts with AML. Human AML-derived ECNV-αGCs activate iNKT cells in both healthy individuals and patients with AML regardless of responsiveness to conventional therapies. Together, autologous AML-derived ECNV-αGCs may be a promising personalized therapeutic vaccine that efficiently establishes AML-specific long-term immunity without requiring the identification of neoantigens
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a acute myeloid leukemia
|
| 650 |
|
4 |
|a cytotoxic T cells
|
| 650 |
|
4 |
|a extracellular nanovesicles
|
| 650 |
|
4 |
|a iNKT cells
|
| 650 |
|
4 |
|a memory immunity
|
| 650 |
|
4 |
|a personalized vaccines
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Hong, Jihye
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Suyoung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koh, Choong-Hyun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kwak, Minkyeong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Byung-Seok
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jung, Mungyo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Yoon-Joo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cho, Byung-Sik
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Byung-Soo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chung, Yeonseok
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 36 vom: 30. Sept., Seite e2303080
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:36
|g day:30
|g month:09
|g pages:e2303080
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202303080
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 36
|b 30
|c 09
|h e2303080
|